Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-dose TPF Induction for Oropharyngeal and Oral Cavity Cancer
NCT01108042Phase 2Completed
- Sponsor
- Orlando Guntinas-Lichius
- Start
- Nov 2009
- Primary completion
- Jan 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, Cisplatin micelle injection (HA132) and fluorouracil in oropharyngeal squamous cell carcinoma (OPSCC) and oral cavity squamous cell carcinoma (OCSCC), sponsored by Orlando Guntinas-Lichius. Primary endpoint: Progression-Free Survival at 24 months. Started Nov 2009; status: completed.
02
Drugs
docetaxelCisplatin micelle injection (HA132)fluorouracil
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)oral cavity squamous cell carcinoma (OCSCC)
Beyond the preview
Go deeper on NCT01108042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01108042.